# Drug Treatment: Resources and Further Reading

## Overview

This document compiles essential resources for understanding drug treatment policy, including landmark reports, key data sources, academic literature, legal references, and advocacy organizations. Resources are organized by category and annotated for relevance.

---

## Landmark Reports and Government Publications

### Federal Reports

| Report | Author | Year | Significance |
|--------|--------|------|-------------|
| *Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health* | U.S. Surgeon General | 2016 | First Surgeon General's report on addiction; comprehensive evidence review |
| *Medications for Opioid Use Disorder Save Lives* | National Academies of Sciences | 2019 | Definitive scientific consensus on MOUD effectiveness |
| *Principles of Drug Addiction Treatment: A Research-Based Guide* (3rd ed.) | NIDA | 2018 | Core treatment principles; foundational for evidence-based practice |
| *TIP 63: Medications for Opioid Use Disorder* | SAMHSA | 2021 | Clinical guidance for MOUD prescribing and management |
| *National Drug Control Strategy* | ONDCP | 2024 | Biden administration drug policy framework |
| *HHS Overdose Prevention Strategy* | HHS | 2024 | Five-pillar federal approach to overdose crisis |
| *2022 National Survey on Drug Use and Health* | SAMHSA | 2023 | Primary national data on SUD prevalence and treatment |

### Congressional Reports

| Report | Author | Year | Significance |
|--------|--------|------|-------------|
| *America's Addiction Crisis: Challenges and Strategies* | Senate HELP Committee | 2022 | Bipartisan assessment of treatment system |
| *Implementation of the SUPPORT Act* | GAO | 2023 | Evaluation of 2018 legislation implementation |
| *Mental Health Parity: Federal Enforcement and State Compliance* | GAO | 2023 | Assessment of MHPAEA enforcement gaps |
| *Opioid Settlement Funds: Early Spending Patterns* | CRS | 2024 | Congressional research on settlement fund deployment |

### State-Level Reports

| Report | Author | Year | Significance |
|--------|--------|------|-------------|
| *Vermont Hub-and-Spoke Treatment System Evaluation* | Vermont ADAP | 2022 | Blueprint for MOUD delivery system |
| *Rhode Island Correctional MOUD Program Evaluation* | Brown University | 2023 | Evidence for statewide correctional MOUD |
| *California Contingency Management Demonstration* | DHCS | 2024 | First Medicaid-funded CM program |
| *Oregon Measure 110 Implementation Assessment* | Oregon Health Authority | 2024 | Decriminalization + treatment investment evaluation |

---

## Academic Literature

### Medication for Opioid Use Disorder

| Citation | Year | Key Finding |
|----------|------|------------|
| Sordo, L., et al. "Mortality risk during and after opioid substitution treatment." *BMJ* 357 (2017): j1550. | 2017 | Systematic review: MOUD reduces all-cause mortality by 50%+ |
| Wakeman, S.E., et al. "Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder." *JAMA Network Open* 3, no. 2 (2020): e1920622. | 2020 | Buprenorphine and methadone associated with 50-80% lower overdose risk vs. no medication |
| National Academies of Sciences. *Medications for Opioid Use Disorder Save Lives*. Washington, DC: National Academies Press, 2019. | 2019 | Scientific consensus that MOUD is most effective OUD treatment |
| D'Onofrio, G., et al. "Emergency Department-Initiated Buprenorphine/Naloxone Treatment for Opioid Dependence." *JAMA* 313, no. 16 (2015): 1636-1644. | 2015 | ED-initiated buprenorphine: 78% engagement at 30 days vs. 37% with referral |
| Haffajee, R.L., et al. "Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder." *JAMA Network Open* 2, no. 6 (2019): e196373. | 2019 | Geographic mismatch between overdose burden and MOUD capacity |

### Treatment Effectiveness

| Citation | Year | Key Finding |
|----------|------|------------|
| McLellan, A.T., et al. "Drug Dependence, a Chronic Medical Illness: Implications for Treatment, Insurance, and Outcomes Evaluation." *JAMA* 284, no. 13 (2000): 1689-1695. | 2000 | Landmark paper establishing addiction as chronic disease comparable to diabetes, hypertension |
| Dennis, M.L., et al. "Managing Addiction as a Chronic Condition." *Current Psychiatry Reports* 7 (2005): 405-411. | 2005 | Evidence for continuing care model in addiction treatment |
| Leshner, A.I. "Addiction Is a Brain Disease, and It Matters." *Science* 278, no. 5335 (1997): 45-47. | 1997 | Foundational articulation of brain disease model |
| Volkow, N.D., and Morales, M. "The Brain on Drugs: From Reward to Addiction." *Cell* 162, no. 2 (2015): 403-413. | 2015 | Neuroscience of addiction and treatment implications |

### Contingency Management

| Citation | Year | Key Finding |
|----------|------|------------|
| Petry, N.M. "Contingency Management: What It Is and Why Psychiatrists Should Want to Use It." *The Psychiatrist* 30, no. 5 (2006): 161-163. | 2006 | Overview of CM principles and effectiveness |
| De Crescenzo, F., et al. "Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction." *PLOS Medicine* 15, no. 12 (2018): e1002715. | 2018 | CM is most effective behavioral intervention for stimulant use |
| McDonell, M.G., et al. "Randomized controlled trial of contingency management for stimulant use in community mental health patients with serious mental illness." *American Journal of Psychiatry* 170, no. 1 (2013): 94-101. | 2013 | CM effective for dual-diagnosis patients |

### Insurance Parity

| Citation | Year | Key Finding |
|----------|------|------------|
| Ettner, S.L., et al. "Benefit mandates for mental health and substance use disorders and utilization and spending among enrollees in employer-sponsored health plans." *Medical Care* 54, no. 11 (2016): 1024-1032. | 2016 | Parity mandates increase SUD treatment utilization |
| Melek, S.P., et al. "Addiction and Mental Health vs. Physical Health: Widening Disparities in Network Use and Provider Reimbursement." Milliman Research Report, 2019. | 2019 | Documents persistent parity violations in network adequacy and reimbursement |
| Kennedy-Hendricks, A., et al. "The Impact of State Mental Health Parity Laws on Access to Treatment." *Health Affairs* 40, no. 10 (2021): 1558-1566. | 2021 | State parity laws associated with 8-12% increase in SUD treatment utilization |

### Stigma

| Citation | Year | Key Finding |
|----------|------|------------|
| Kelly, J.F., and Westerhoff, C.M. "Does It Matter How We Refer to Individuals with Substance-Related Conditions?" *International Journal of Drug Policy* 21, no. 3 (2010): 202-207. | 2010 | Language affects perception: "substance abuser" vs. "person with SUD" |
| McGinty, E.E., and Barry, C.L. "Stigma Reduction to Combat the Addiction Crisis." *New England Journal of Medicine* 382 (2020): 1291-1292. | 2020 | Evidence-based stigma reduction strategies for addiction |
| Tsai, A.C., et al. "Stigma as a Fundamental Hindrance to the United States Opioid Overdose Crisis Response." *PLOS Medicine* 16, no. 11 (2019): e1002969. | 2019 | Stigma undermines every dimension of the overdose response |

---

## Data Sources

### National Surveys and Databases

| Source | Publisher | Frequency | Content |
|--------|-----------|-----------|---------|
| National Survey on Drug Use and Health (NSDUH) | SAMHSA | Annual | SUD prevalence, treatment receipt, demographics |
| National Survey of Substance Abuse Treatment Services (N-SSATS) | SAMHSA | Annual | Treatment facility characteristics, services offered |
| Treatment Episode Data Set (TEDS) | SAMHSA | Annual | Treatment admissions and discharges by demographics and substance |
| Drug Abuse Warning Network (DAWN) | SAMHSA | Periodic | Drug-related emergency department visits |
| National Vital Statistics System | CDC/NCHS | Continuous | Overdose death data |
| CDC WONDER | CDC | Continuous | Multiple-cause-of-death data, including drug overdose |
| Automation of Reports and Consolidated Orders System (ARCOS) | DEA | Annual | Controlled substance distribution data (methadone, buprenorphine) |
| SAMHSA OTP Directory | SAMHSA | Updated regularly | Opioid Treatment Program locations and status |
| SAMHSA Treatment Locator | SAMHSA | Updated regularly | Searchable treatment facility directory |

### Economic and Policy Data

| Source | Publisher | Content |
|--------|-----------|---------|
| National Drug Control Budget | ONDCP | Federal drug control spending by function |
| Medicaid SUD expenditure reports | CMS | Medicaid SUD spending by state and service |
| Kaiser Family Foundation State Health Facts | KFF | Medicaid expansion, SUD policy by state |
| Mental Health Parity compliance data | DOL | MHPAEA enforcement actions and investigations |
| Opioid Settlement Tracker | various | Settlement fund distribution and spending |

---

## Legal References

### Federal Statutes

| Statute | Citation | Relevance |
|---------|----------|-----------|
| Controlled Substances Act | 21 U.S.C. ch. 13 | Drug scheduling; DEA authority; treatment medication classification |
| Drug Addiction Treatment Act of 2000 (DATA 2000) | Pub. L. 106-310, Title XXXV | Created X-waiver for buprenorphine (eliminated 2023) |
| Mental Health Parity and Addiction Equity Act (MHPAEA) | 29 U.S.C. 1185a | Insurance parity for SUD and mental health |
| Affordable Care Act | Pub. L. 111-148 | Essential health benefits; Medicaid expansion; parity strengthening |
| Comprehensive Addiction and Recovery Act (CARA) | Pub. L. 114-198 | NP/PA prescribing; naloxone; recovery support |
| SUPPORT for Patients and Communities Act | Pub. L. 115-271 | Medicaid IMD waiver; telehealth; SUD treatment expansion |
| 21st Century Cures Act | Pub. L. 114-255 | $1 billion SOR grants; mental health and SUD provisions |
| Consolidated Appropriations Act, 2023 | Pub. L. 117-328 | X-waiver elimination (Section 1262) |
| Harrison Narcotics Tax Act (historical) | Pub. L. 63-223 (1914) | First federal drug control law; criminalized addiction maintenance |

### Key Federal Regulations

| Regulation | Citation | Content |
|-----------|----------|---------|
| Opioid Treatment Program regulations | 42 CFR Part 8 | OTP certification, methadone dispensing, take-home doses |
| SUD patient records confidentiality | 42 CFR Part 2 | Privacy protections for SUD treatment records |
| DEA practitioner registration | 21 CFR Part 1301 | DEA registration for controlled substance prescribing |
| MHPAEA final rule (2024) | 29 CFR Part 2590 | Strengthened parity enforcement; NQTL comparative analysis |

### Key Court Cases

| Case | Citation | Significance |
|------|----------|-------------|
| *Webb v. United States* | 249 U.S. 96 (1919) | Criminalized addiction maintenance prescribing |
| *Linder v. United States* | 268 U.S. 5 (1925) | Narrowed Webb; physicians may treat addiction |
| *Robinson v. California* | 370 U.S. 660 (1962) | Addiction is an illness; cannot be criminalized as status |
| *Pesce v. Coppinger* | 355 F. Supp. 3d 35 (D. Mass. 2018) | Preliminary injunction requiring jail to provide MOUD |
| *Smith v. Aroostook County* | No. 1:18-cv-00015 (D. Me. 2019) | Settlement requiring county jail to provide MOUD |
| *Wit v. United Behavioral Health* | No. 14-cv-02346 (N.D. Cal. 2019) | Insurance company violated ERISA by applying unduly restrictive treatment criteria |

---

## Organizations and Advocacy Groups

### Federal Agencies

| Organization | Website | Role |
|-------------|---------|------|
| SAMHSA | samhsa.gov | Primary federal SUD treatment agency |
| NIDA | nida.nih.gov | Addiction research |
| NIAAA | niaaa.nih.gov | Alcohol research |
| CDC Injury Center | cdc.gov/injury | Overdose surveillance |
| CMS | cms.gov | Medicaid/Medicare SUD policy |
| ONDCP | whitehouse.gov/ondcp | National drug control policy |

### National Advocacy Organizations

| Organization | Website | Focus |
|-------------|---------|-------|
| Shatterproof | shatterproof.org | Treatment quality, parity, public education |
| Partnership to End Addiction | drugfree.org | Family support, prevention, treatment access |
| Faces & Voices of Recovery | facesandvoicesofrecovery.org | Recovery advocacy, community organizing |
| National Alliance for Medication Assisted Recovery (NAMA) | methadone.org | MOUD patient advocacy |
| Drug Policy Alliance | drugpolicy.org | Drug policy reform, decriminalization |
| Legal Action Center | lac.org | SUD legal rights, discrimination, privacy |
| Kennedy Forum | thekennedyforum.org | Mental health and SUD parity |
| National Council for Mental Wellbeing | thenationalcouncil.org | Provider advocacy, integrated care |

### Professional Organizations

| Organization | Website | Focus |
|-------------|---------|-------|
| American Society of Addiction Medicine (ASAM) | asam.org | Addiction medicine standards, advocacy |
| American Academy of Addiction Psychiatry (AAAP) | aaap.org | Addiction psychiatry education, advocacy |
| NAADAC (Association for Addiction Professionals) | naadac.org | Addiction counselor education, certification |
| American Association for the Treatment of Opioid Dependence (AATOD) | aatod.org | OTP advocacy, policy |
| National Association of Recovery Residences (NARR) | narronline.org | Recovery housing standards, certification |

### Research and Policy Organizations

| Organization | Website | Focus |
|-------------|---------|-------|
| RAND Drug Policy Research Center | rand.org/health-care/centers/dprc | Drug policy research and evaluation |
| Recovery Research Institute (Harvard/MGH) | recoveryanswers.org | Recovery science and public education |
| Pew Charitable Trusts (SUD) | pewtrusts.org | State policy research and advocacy |
| KFF (Kaiser Family Foundation) | kff.org | Health policy data and analysis |
| Brookings Institution | brookings.org | Drug policy research |

---

## Essential Reading List

### For Policymakers

1. National Academies. *Medications for Opioid Use Disorder Save Lives* (2019)
2. Surgeon General. *Facing Addiction in America* (2016)
3. SAMHSA. *TIP 63: Medications for Opioid Use Disorder* (2021)
4. NIDA. *Principles of Drug Addiction Treatment* (3rd ed., 2018)
5. Pew Charitable Trusts. *State Strategies to Increase Treatment Access* (2023)

### For Healthcare Providers

1. ASAM. *ASAM National Practice Guideline for the Treatment of Opioid Use Disorder* (2020)
2. SAMHSA. *TIP 63: Medications for Opioid Use Disorder* (2021)
3. NIDA. *Principles of Drug Addiction Treatment* (3rd ed., 2018)
4. APA. *Practice Guideline for the Treatment of Substance Use Disorders* (2023)
5. SAMHSA. *Advisory: Use of Medication-Assisted Treatment for Opioid Use Disorder in the Criminal Justice System* (2019)

### For Advocates and Citizens

1. Macy, Beth. *Dopesick: Dealers, Doctors, and the Drug Company That Addicted America* (2018)
2. McGovern, Patrick. *If You Love Me: A Mother's Journey Through Her Daughter's Opioid Addiction* (2018)
3. Hart, Carl. *Drug Use for Grown-Ups: Chasing Liberty in the Land of Fear* (2021)
4. Szalavitz, Maia. *Undoing Drugs: The Untold Story of Harm Reduction* (2021)
5. Partnership to End Addiction. *Navigating Addiction and Treatment* (online resource)

---

## Document Navigation

| Previous | Next |
|----------|------|
| [Roadmap](08-roadmap.md) | [Actions](10-actions.md) |

**Section Navigation:**
[Overview](01-overview.md) | [Current State](02-current-state.md) | [History](03-history.md) | [Root Causes](04-root-causes.md) | [Stakeholders](05-stakeholders.md) | [Opposition](06-opposition.md) | [Solutions](07-solutions.md) | [Roadmap](08-roadmap.md) | [Resources](09-resources.md) | [Actions](10-actions.md) | [Legislation](11-legislation.md) | [Perspectives](12-perspectives.md)
